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Abstract
Background: Observational data associate lower levels of serum vitamin D with coronary artery calcification, cardiovascular
events and mortality. However, there is little interventional evidence demonstrating that moderate vitamin D deficiency
plays a causative role in cardiovascular disease. This study examined the cardiovascular effects of dietary vitamin D
deficiency and of vitamin D receptor agonist (paricalcitol) administration in apolipoprotein E knockout mice.
Methods: Mice were fed atherogenic diets with normal vitamin D content (1.5IU/kg) or without vitamin D. Paricalcitol, or
matched vehicle, was administered 36 weekly by intraperitoneal injection. Following 20 weeks of these interventions
cardiovascular phenotype was characterized by histological assessment of aortic sinus atheroma, soluble markers, blood
pressure and echocardiography. To place the cardiovascular assessments in the context of intervention effects on bone,
structural changes at the tibia were assessed by microtomography.
Results: Vitamin D deficient diet induced significant reductions in plasma vitamin D (p,0.001), trabecular bone volume (p,
0.01) and bone mineral density (p,0.005). These changes were accompanied by an increase in calcification density (number
of calcifications per mm2) of von Kossa-stained aortic sinus atheroma (461 versus 200, p,0.01). Paricalcitol administration
suppressed parathyroid hormone (p,0.001), elevated plasma calcium phosphate product (p,0.005) and induced an
increase in calcification density (472 versus 200, p,0.005) similar to that seen with vitamin D deficiency. Atheroma burden,
blood pressure, metabolic profile and measures of left ventricular hypertrophy were unaffected by the interventions.
Conclusion: Vitamin D deficiency, as well as excess, increases atherosclerotic calcification. This phenotype is induced before
other measures of cardiovascular pathology associated clinically with vitamin D deficiency. Thus, maintenance of an optimal
range of vitamin D signalling may be important for prevention of atherosclerotic calcification.
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Introduction
Lower levels of circulating active vitamin D (calcitriol) or its
precursor, 25-hydroxy vitamin D (25(OH)D), predict increased
risk of myocardial infarction [1,2], stroke [3,4] and cardiovascular
death [5,6]. Measures of cardiovascular disease associated with
lower vitamin D levels in cross sectional analyses include
endothelial dysfunction [7], coronary calcification [8] and arterial
stiffness [9]. Cardiovascular risk factors such as hypertension [10],
diabetes [11,12], obesity [12] and dyslipidemia [13] are also
associated with lower vitamin D levels. These observations are
reported across strata of vitamin D concentration in community
populations, giving rise to debate regarding definitions of vitamin
D deficiency or ‘insufficiency’ [14]. However, it remains unclear
whether the reported associations reflect residual confounding
from nutrition and lifestyle [13,14]. Interventional data demon-
strating benefits of vitamin D supplementation on clinical
cardiovascular endpoints are awaited [15,16].
The conversion of 25(OH)D to calcitriol is performed by the
enzyme one-alpha hydroxylase and occurs primarily in the kidney,
regulated by parathyroid hormone, phosphate and fibroblast
growth factor-23. Calcitriol acts on the nuclear vitamin D receptor
(VDR) to stimulate increased intestinal calcium and phosphate
uptake and promote bone mineralization. However, the VDR is
also expressed in vascular smooth muscle cells [17], endothelial
cells [18], macrophages [19] and cardiomyocytes [20]. Concurrent
expression of one-alpha hydroxylase in these cell types suggests a
possible paracrine role for vitamin D signalling in the cardiovas-
cular system [21].
Vitamin D receptor knockout (VDR2/2) mice manifest
increased renin secretion, hypertension and left ventricular
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hypertrophy [22]. Accelerated atherogenesis has also been
reported to accompany VDR knockout in atheroma-prone LDL
cholesterol receptor deficient mice [23]. However, the VDR2/2
phenotype includes growth retardation, marked hyperparathy-
roidism, alopecia, and severe bone disease [24]. Cardiovascular
findings in this genetic model thus may not be relevant to the
above clinical observations (described in populations without
osteomalacia). We therefore examined the cardiovascular effects of
manipulating vitamin D signalling using vitamin D deficient diets
and a VDR agonist in atheroma-prone apolipoprotein E knockout
(ApoE2/2) mice. Specifically, we hypothesized that: 1) dietary
vitamin D deficiency increases aortic sinus atheroma burden,
atheroma calcification and left ventricular hypertrophy (LVH),
and 2) administration of active vitamin D suppresses atheroma
formation and LVH.
Materials and Methods
Animals and Interventions
ApoE2/2 mice on a C57BL/6 background were obtained from
a breeding colony maintained in our unit (original source JAX
Labs; JAX2052). Eight week-old males were randomly assigned to
vitamin D replete (1.5IU/kg) or deficient (no vitamin D)
atherogenic diets (20% cocoa butter, 0.2% cholesterol, 0.03%
cholate) with standard calcium (1%) and phosphate (0.6%) content
(Harlan Teklad, USA). Between weaning and commencement of
test diets, a vitamin D replete diet (1.5IU/kg) was used (Special
Diet Services, UK). Animals were housed in a controlled 22uC
environment with 12h fluorescent light/dark cycle and free access
to food and water.
In an initial experiment the effects of 12 weeks of vitamin D
deficient versus replete diet on plasma 25(OH)D levels and bone
structure were determined (n = 4 animals per group). Following
confirmation of meaningful effects of the dietary intervention, a
second experiment examined the cardiovascular consequences of
dietary vitamin D deficiency induced by a 20 week intervention
period.
From each dietary group (vitamin D replete and vitamin D
deficient) animals were further randomized to receive the active
vitamin D analogue paricalcitol (Abbott) 400 ng/kg or matched
vehicle (20% v/v ethanol, 30% v/v propylene glycol, 50% water)
by intraperitoneal injection 36weekly over the same intervention
period (giving 4 groups of n= 7–8 per group). This paricalcitol
dose has previously been shown to be well tolerated and to correct
secondary hyperparathyroidism in partial renal ablation models
[25,26]. After 20 weeks of intervention animals were euthanized
under pentobarbitone anaesthesia. All experiments were approved
by the University of Sheffield Project Review Committee and
conformed to UK Home Office Regulations (Animal Scientific
Procedures Act 1986; Project Licence PPL40/3307).
Blood Pressure Measurements
Tail cuff blood pressure measurements were performed at 2-
weekly intervals on 4 animals per intervention group (Visitech
2000, Visitech Systems, USA). Measurements were taken at the
same time of day on each occasion at a controlled temperature of
30uC. An initial set of 10 acclimatization readings were performed
prior to the collection of measurements for analysis. Results were
based on readings from 20 subsequent cuff inflations per animal,
with a mean number of 12 successful readings per session. Mean
arterial pressure was calculated from each pair of systolic and
diastolic readings.
Plasma Biochemistry
Plasma calcium, phosphate, urea and lipid fractions were
measured by automated bioanalyzer (Beckman Coulter DxC).
Whole blood fasting glucose concentration was measured using a
portable glucometer (Optium Xceed, Medisense, UK) and
commercial ELISAs were used to quantify plasma parathyroid
hormone (Immutopics, USA), 25(OH)D (Immunodiagnostic Sys-
tems, UK), soluble vascular cell adhesion molecule-1 (sVCAM-1)
(R and D Systems, USA) and insulin (Crystalchem, USA). Insulin
resistance was measured by homeostatic model assessment
(HOMA-IR), calculated as fasting plasma insulin (ng/mL)6fasting
plasma glucose (mg/dL)/405. The total plasma nitric oxide
oxidation product concentration was measured by Sievers analyser
(GE Analytical Instruments, UK).
Bone Microtomography
The effects of dietary manipulation and paricalcitol on bone
structure were assessed by high resolution microtomography
(Skyscan, Belgium) analysis of the right tibia. Trabecular bone
volume and density were determined using image analysis software
with images obtained from a 1 mm length of bone extending
distally from 0.2 mm beyond the proximal growth plate.
Tissue Collection and Preparation
Following aspiration of blood by cardiac puncture the
vasculature was flushed with phosphate-buffered saline (PBS)
and perfusion-fixed by ventricular injection of 10% v/v formalin.
Thoracic aortae were dissected free of connecting tissue from the
heart to the level of the diaphragm and fixed in 4% w/v
paraformaldehyde for 24h, then stored in PBS prior to staining.
After fixation in 10% formalin hearts and brachiocephalic arteries
were dehydrated and embedded in paraffin wax for section
cutting.
Assessment of Atheroma Burden/Character
Atheroma burden was quantified in 5 evenly spaced 7 mm cross-
sections through the aortic sinus at the level of the aortic valves.
Sections were stained with alcian blue/Miller’s elastin van Gieson
for atheroma quantification, which was expressed as the mean
percentage cross sectional area occupied by atheroma; lumen area
was calculated from perimeter measurements. Based on our
previous results using similar dietary interventions in ApoE2/2
mice [27], the group sizes gave 80% power to detect a mean
difference of 30% in aortic sinus cross sectional atheroma burden
at alpha= 0.05. Additional assessment of atheroma burden was
performed in en face preparations of the thoracic aorta stained for
lipid with oil red-O. Determination of the percentage acellular
atheroma lesion area was performed on sections stained with
haematoxylin/eosin. Morphometric analysis software (NIS-ele-
ments Br 3.0, Nikon Instruments, USA) was used for all analyses of
atheroma burden and character, by a single assessor blinded to the
intervention group.
Assessment of Atheroma Calcification
For quantification of atheroma calcification, aortic sinus
sections were stained by von Kossa’s method with 2% w/v silver
nitrate and a nuclear fast red counterstain. Number and area of
calcifications were measured using automated software (NIS-
elements Br 3.0, Nikon Instruments, USA) with a light wavelength
threshold set to identify the black positive (silver salt) von Kossa
stain. Since a small number of large calcifications dominated the
total calcified lesion area measurements, meaningful statistical
comparisons of percentage calcified area between groups were not
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possible. Similarly, comparing the number of plaques classified as
globally calcified (such as applied to human post-mortem studies
[28]) was not statistically feasible because there were few lesions
with large calcifications. Therefore, diffuse atheromatous calcifi-
cation was examined with the approach adopted by Schmidt et al.
of quantifying the number of distinct calcifications (subanalyzed by
size $/,100 mm2) [29], indexed to atherosclerotic lesion area.
The total number of calcifications per mm2 atheroma area was
considered a measure of diffuse calcification density. Percentage
calcified area attributable to calcifications ,100 mm2 was also
compared across intervention groups. The large number of
calcifications ,100 mm2, distributed diffusely in all plaques,
allowed a more robust statistical comparison of calcification
character by these measures.
Immunohistochemical Analysis of Aortic Roots
For immunohistochemistry of aortic sinus sections endogenous
peroxidases were blocked by immersion in 3% v/v hydrogen
peroxide in PBS for 10 min. Antigen retrieval was performed with
10% v/v pH6 citrate buffer (Dako, Germany) in water at 95uC for
20 min and sections were then permeabilized with 0.5% v/v triton
X-100 (Sigma) for 5 min at room temperature. Incubation in milk
buffer for 30 min was used to block nonspecific antibody binding.
Following washing in PBS, sections were incubated with primary
antibodies to osteopontin (ab8488, Abcam, UK) at 1:150 dilution
overnight at 4uC, then incubated with horseradish peroxidase-
conjugated goat anti-rabbit secondary antibody (P0448, Dako,
Denmark) at 1:200 dilution for 30 min. After repeated washing in
PBS, complexes were visualized with diaminobenzidine and
sections counterstained with Carazzi’s haematoxylin. Staining
was quantified by image analysis software (NIS-elements Br 3.0,
Nikon Instruments, USA).
Echocardiography and Left Ventricular Morphology
Transthoracic echocardiography was performed under isofluor-
ane anaesthesia at week 18–19 (n= 5–6 per group) by a single
operator blinded to the experimental status of the mice. Short axis
views of the left ventricle (LV) were obtained at the mid papillary
muscle level (Vevo 770 ultrasound, Visual Sonics, Canada) and
fractional area change determined by manual tracing of the LV
wall end diastolic and end systolic areas. Ventricular wall and
cavity dimensions were assessed with M-mode measurements;
ejection fraction was determined from these measurements by
automated software (Visual Sonics). Pulse wave doppler at the
aortic annulus was used to measure the velocity timed integral of
aortic flow, which was multiplied by the LV outflow tract area to
calculate stroke volume and cardiac output. Cardiac output was
indexed to body weight for each mouse.
Histological analyses of LV morphology and cardiomyocyte size
were performed on haematoxylin/eosin-stained 7 mm sections
through the left ventricle 500 mm below the inferior edge of the
mitral valve. Mean cardiomyocyte area and diameter were
determined from measurements on 50 cells in transverse and
longitudinal cross section respectively per mouse (image analysis
software as above).
Statistical Analysis
Data are presented as mean 6standard error. Analyses were
performed using GraphPad Prism software version 5 (GraphPad,
USA). Groups were compared by one-way ANOVA with
Bonferroni correction for multiple comparisons.
Results
The Effects of Vitamin D Deficient Diet and Paricalcitol on
Plasma Biochemistry and Bone Structure
Feeding a vitamin D deficient diet induced significant reduc-
tions in plasma 25(OH)D levels, trabecular bone volume and bone
mineral density (Figure 1). These changes were apparent by 12
weeks of dietary intervention (Figure S1), confirming that the 20
week intervention gave a meaningful period of exposure to vitamin
D deficiency. Vitamin D deficient diet did not change plasma
calcium or phosphate levels (Table 1). However, administration of
paricalcitol caused a significant increase in plasma calcium
concentration and calcium x phosphate product, accompanied
by suppression of parathyroid hormone. When given to mice on a
vitamin D replete diet paricalcitol also reduced plasma 25(OH)D
levels, consistent with negative feedback induction of 25(OH)D
catabolism [30]. Despite the increase in plasma calcium induced
by administration of paricalcitol to animals with dietary vitamin D
deficiency, trabecular bone changes were not reversed.
Vitamin D Manipulation does not Affect Blood Pressure,
Nitric Oxide Metabolites or Metabolic Profile
Manipulation of vitamin D status by feeding a vitamin D
deficient diet or the administration of paricalcitol resulted in
significantly lower average chow consumption, but did not
significantly change the lipid profile, fasting glucose, insulin
resistance or body mass index (Table 2). Total plasma nitric oxide
metabolites were not suppressed by dietary vitamin D deficiency
nor significantly increased by paricalcitol administration. Soluble
VCAM-1 levels were also not significantly different between
groups. Tail cuff systolic, diastolic and mean blood pressure did
not differ significantly by intervention at any stage (Figure 2).
Atheroma Calcification is Increased by Dietary Vitamin D
Deficiency but Atheroma Burden is Not
Atheroma burden measured in cross sections at the aortic sinus
or in en face preparations of the thoracic aorta was not
significantly different between groups (Figure 3A,B and Figure
S2). Atheroma cellularity and the percentage area occupied by
lipid clefts were also unaffected by vitamin D manipulation
(Figure 3C,D).
There was a significant increase in the diffuse calcification of
aortic sinus atherosclerosis assessed by von Kossa staining in mice
fed a vitamin D deficient diet or administered paricalcitol
(Figures 4 and 5). Small calcifications (,100 mm2) were present
diffusely throughout the atherosclerotic lesions (Figure 4A–D); a
small number of much larger calcifications were also present in
association with necrotic regions in all groups (Figure 4E–G). The
total number of calcifications per mm2 lesion area was more than
doubled in mice fed a vitamin D deficient diet or administered
paricalcitol compared to mice fed a vitamin D replete diet. Total
percentage calcified lesion area was also greater in vitamin D-
deficient mice and mice administered paricalcitol, but this was not
statistically significant, reflecting the small number of very large
calcifications dominating the total calcified area measurement.
The number of large calcifications ($100 mm2) was also nonsig-
nificantly greater in atheroma from vitamin D deficient and
paricalcitol-treated mice versus D-replete diet vehicle-treated
mice. When the percentage calcified lesion area attributable to
the diffuse small lesions (,100 mm2) was considered, this was
significantly greater for vitamin D deficient mice (p,0.05 vs. mice
on vitamin D replete diet) and paricalcitol-administered mice (p,
0.01 vs. mice on a vitamin D replete diet). The percentage calcified
Vitamin D Manipulation in ApoE2/2 Mice
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Figure 1. Effects of 20 weeks of vitamin D deficient diet and paricalcitol on 25(OH)D and bone structure. A, plasma 25(OH)D by
intervention. B, trabecular bone volume by intervention. C, trabecular bone mineral density relative to that of mice fed a vitamin D replete diet. D,
representative microCT images of trabecular bone after 20 weeks of interventions. Groups are labelled according to dietary vitamin D content. Mice
that did not receive paricalcitol received matched vehicle. D+, vitamin D replete diet; D-, vitamin D deficient diet; D+/P, vitamin D replete diet with
paricalcitol, D2/P, vitamin D deficient diet with paricalcitol. n = 7–8 per group, data presented as mean (SEM). *p,0.05, **p,0.01, ***p,0.005,
****p,0.001. BMD, bone mineral density; TB, trabecular bone.
doi:10.1371/journal.pone.0088767.g001
Table 1. Effects of vitamin D deficient diet and paricalcitol on calcium, phosphate and parathyroid hormone.
Vit D replete plus
vehicle
Vit D deficient plus
vehicle
Vit D replete plus
paricalcitol
Vit D deficient plus
paricalcitol
Calcium (Ca), mmol/L 2.33 (0.02) 2.31 (0.03) 2.72 (0.10)* 2.53 (0.05)*
Phosphate (Pi), mmol/L 2.37 (0.16) 2.32 (0.12) 2.67 (0.13) 2.86 (0.15)
Ca x Pi product, mmol2/L2 4.91 (0.70) 5.36 (0.31) 7.30 (0.57)* 7.25 (0.45)*
PTH, ng/L 165 (17) 194 (16) 77 (7){ 68 (3){
n= 7–8 per group, data are given as mean (SEM).
*p,0.005 vs. D replete vehicle, {p,0.001 vs. D replete vehicle. PTH, parathyroid hormone.
doi:10.1371/journal.pone.0088767.t001
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aortic valve area and number of valve calcifications per mm2 did
not differ significantly between groups (not shown). Immunostain-
ing did not show any significant differences in atheroma or valve
osteopontin expression. As previously reported [31], intense
staining for osteopontin was evident at sites of dystrophic
calcification (Figure 4E–G).
Left Ventricular Hypertrophy is not Induced by Dietary
Vitamin D Deficiency in ApoE2/2 Mice
Cardiac weights did not differ between the intervention groups
(Figure 6). Histological assessment of LV morphology including
mean LV wall thickness, LV wall cross sectional area, cardiomy-
ocyte transverse area and cardiomyocyte diameter also did not
show any differences between groups. Echocardiographic func-
tional parameters of ejection fraction, fractional area change and
cardiac index were similarly unchanged.
Discussion
Despite the large body of observational data linking lower
vitamin D levels to cardiovascular disease, interventional evidence
for a causative role of lower vitamin D levels in cardiovascular
pathology is relatively scarce. We report the novel finding that
dietary vitamin D deficiency induces a substantial increase in
diffuse atherosclerotic calcification. The extent of this increase is
similar to that induced by the administration of a VDR agonist
dose sufficient to raise the plasma calcium phosphate product, a
recognised stimulus to arterial calcification in nonatheromatous
animal models [32]. The increase in diffuse atherosclerotic
calcification induced by vitamin D deficiency occurred at a degree
of deficiency where no increases in atheroma burden, metabolic
derangement or left ventricular hypertrophy were evident.
These results with regard to calcification are consistent with
clinical observational data. Lower 25(OH) vitamin D levels were
an independent predictor of coronary artery calcification in an
asymptomatic population [33] and polymorphisms in the vitamin
D regulatory gene CYP24A1 have been associated with coronary
calcification in a cross-sectional analysis [34]. However, standard
clinical assessments do not distinguish between calcification
Figure 2. Vitamin D manipulation does not affect blood
pressure in ApoE2/2 mice. A, mean tail cuff blood pressure by
week. B, time-averaged mean blood pressures. n = 4 per group, data
presented as mean (SEM). D+, vitamin D replete diet; D-, vitamin D
deficient diet; D+/P, vitamin D replete diet with paricalcitol, D2/P,
vitamin D deficient diet with paricalcitol.
doi:10.1371/journal.pone.0088767.g002
Table 2. Effects of vitamin D deficient diet and paricalcitol on metabolic profile.
Vit D replete plus
vehicle
Vit D deficient plus
vehicle
Vit D replete plus
paricalcitol
Vit D deficient plus
paricalcitol
Cholesterol, mmol/L 23.5 (1.8) 20.7 (0.9) 27.2 (1.6) 24.9 (3.0)
HDL cholesterol, mmol/L 7.0 (0.4) 6. 9 (0.4) 7.9 (0.8) 7.5 (0.9)
LDL cholesterol, mmol/L 15.5 (1.5) 13.2 (0.5) 18.9 (1.3) 16.8 (2.6)
Triglyceride, mmol/L 1.0 (0.2) 1.2 (0.2) 1.1 (0.1) 1.0 (0.1)
Urea, mmol/L 8.8 (0.5) 9.9 (0.4) 9.4 (0.8) 8.6 (0.4)
Chow consumption, g/day 3.0 (0.0) 2.6 (0.0){ 2.6 (0.0){ 2.7 (0.0)#
Fasting glucose, mmol/L 11.9 (0.5) 12.7 (0.8) 11.8 (0.8) 11.6 (0.8)
HOMA-IR 0.18 (0.03) 0.24 (0.03) 0.25 (0.06) 0.24 (0.05)
NOx metabolites, nmol/ml 6.5 (1.7) 6.6 (1.4) 6.3 (0.9) 10.8 (3.3)
sVCAM, ng/ml 17.9 (0.6) 19.3 (0.9) 20.3 (0.6) 19.4 (0.5)
Final weight, g 31.8 (1.3) 30.0 (1.0) 32.3 (0.7) 29.5 (0.8)
Body length, mm 177.8 (1.4) 178.3 (2.2) 182.0 (0.8) 176.8 (1.2)
Final BMI, kg/m2 0.94 (0.04) 0.90 (0.03) 0.90 (0.02) 0.90 (0.01)
n = 7–8 per group, data are given as mean (SEM).
#p,0.01 vs. D replete vehicle, {p,0.001 vs. D replete vehicle. NOx, nitric oxide; sVCAM, soluble vascular cell adhesion molecule.
doi:10.1371/journal.pone.0088767.t002
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Figure 3. Vitamin Dmanipulation does not affect atheroma burden, cellularity or lipid cleft area. A, aortic sinus cross sectional atheroma
burden. B, thoracic aorta en face atheroma burden. C, percentage of acellular atherosclerosis. D, percentage atheroma cross sectional area occupied
by lipid clefts. n = 7–8 per group, data presented as mean (SEM).
doi:10.1371/journal.pone.0088767.g003
Figure 4. Patterns of atheromatous calcification in ApoE2/2 mice. A–D, representative atherosclerotic lesions demonstrating diffuse
calcification (stained black by von Kossa method, arrows) from mice fed vitamin D replete and vitamin D deficient diets and coadministered vehicle (A
and B respectively) or paricalcitol (C and D respectively). E–G, sequential sections stained with Miller’s elastin Van Gieson, von Kossa method and
osteopontin-specific antibody respectively, demonstrating a necrotic area of lesion (E) containing a large calcification (F) with associated osteopontin
staining (G) (arrows), taken from a vitamin D replete mouse administered paricalcitol.
doi:10.1371/journal.pone.0088767.g004
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differences due to changes in atheroma character, atheroma
burden and nonatherosclerotic medial calcification. To our
knowledge, whether vitamin D status predicts atheroma calcifica-
tion on intravascular ultrasound has not been reported.
Our findings support and extend those of a recent study
reporting that a low vitamin D diet increased the calcified area of
aortic sinus sections in LDL receptor knockout (LDLR2/2) mice
[29]. That report did not, however, determine whether the
location of the increased calcification was in atheroma or the
aortic valves. Also consistent with our findings, Mathew et al.
reported suppression of aortic atherosclerotic calcification by low
doses of active vitamin D in partially nephrectomised LDLR2/2
mice, suggesting restoration of a calcification-inhibitory effect of
VDR signalling [26]. High doses of paricalcitol increased aortic
calcium content in their model, as in our study, consistent with
there being an optimum range of VDR signalling for calcification
prevention.
Our findings are also consistent with some evidence for a
beneficial effect of VDR signalling in the prevention of arterial
medial calcification (as occurs in kidney disease). Vitamin D
receptor agonists (at non-hypercalcemic/hyperphosphatemic dos-
es) have been shown to suppress medial calcification in a high-
phosphate diet partial renal ablation mouse model [35]. Whether
dietary vitamin D deficiency accelerates arterial medial calcifica-
tion is unknown; nonatherosclerotic medial calcification was not
prominent in our model and requires induction by precipitating
factors in animal models (such as renal ablation combined with
high phosphate intake [35]). However, some evidence of a bi-
modal relationship between vitamin D status and vascular
calcification score has been reported in pediatric dialysis patients
[36].
Addition of paricalcitol or calcitriol to vascular smooth muscle
cell-macrophage cocultures has previously been demonstrated to
inhibit phosphate-induced smooth muscle cell calcification via a
mechanism involving stimulation of macrophage osteopontin
Figure 5. Vitamin D deficiency and excess similarly increase atherosclerotic calcification. A, number of calcifications normalized to lesion
area. B, percentage calcified lesion area due to calcifications ,100 mm2. C, number of very large calcifications ($100 mm2). D, total calcified area due
to diffuse and large calcifications. n = 7–8 per group, data presented as mean (SEM). *p,0.05, **p,0.01, ***p,0.005.
doi:10.1371/journal.pone.0088767.g005
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expression [37]. We did not find any difference in atherosclerotic
lesion osteopontin expression accompanying vitamin D manipu-
lation in our model. However this does not mean that osteopontin
is not responsible for mediating anticalcific effects of vitamin D;
osteopontin is expressed at sites of vascular calcification so may be
both a marker and inhibitor of calcification processes [31].
Schmidt et al. reported increased osteopontin expression accom-
panying the increased calcification induced by vitamin D
deficiency [29].
Figure 6. Vitamin D deficiency does not induce left ventricular hypertrophy in ApoE2/2 mice. A, heart weights by intervention. B and C,
mean LV wall thickness and LV cross sectional area measured histologically. D and E, cardiomyocyte cross sectional area and transverse diameter. F,
left ventricular ejection fraction. G, left ventricular fractional area change. H, cardiac index. n = 7–8 per group for histological analyses and weights,
n = 5–6 per group for echocardiography. Data presented as mean (SEM).
doi:10.1371/journal.pone.0088767.g006
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The type of vitamin D therapy as well as the dose could be
clinically important for calcification prevention. Activated vitamin
D (calcitriol) or analogues (such as paricalcitol) act systemically to
increase intestinal calcium and phosphate uptake, bypassing the
regulatory control of renal vitamin D activation. As seen in our
model and others [26,32], the resulting increase in plasma calcium
and phosphate levels may be accompanied by an increase in
vascular calcification. Replenishing instead the precursor,
25(OH)D, could restore paracrine vitamin D signalling in
cardiovascular tissue without necessarily raising plasma calcium
phosphate product. This is of particular clinical relevance in the
setting of chronic kidney disease, where a deficiency of renal
vitamin D activation is commonly accompanied by nutritional
vitamin D deficiency [38]. Our findings suggest that correcting
25(OH) vitamin D deficiency might be beneficial for the
prevention of vascular calcification in these patients. Treating
with an active vitamin D analogue without replenishing 25(OH)D
theoretically risks combining the adverse consequences of
increased calcium phosphate product with persisting deficiency
of paracrine vitamin D signalling. In our model, combining
paricalcitol administration with 25(OH)D deficiency did not result
in a greater degree of atherosclerotic calcification than either
intervention alone. However, although the dose of paricalcitol we
employed was sufficient to raise calcium phosphate product, it did
not restore structural bone changes resulting from 25(OH)D
deficiency. Bone marrow stromal cells express 1-alpha hydroxylase
[39] so our findings may reflect an important role for local
25(OH)D activation in maintaining bone structure. To our
knowledge there are no clinical studies examining differential
effects on bone structure of 25(OH)D replacement versus active
vitamin D administration in the setting of 25(OH)D deficiency.
As in the LDLR2/2 model of Schmidt et al. [29], we found no
significant increase in aortic atherosclerosis burden in ApoE2/2
mice fed a vitamin D-deficient diet. This is in contrast to the
previously reported acceleration of atherogenesis in LDLR2/2
mice crossed with VDR2/2 mice [23], perhaps reflecting a lesser
degree of attenuation of vitamin D signalling by our dietary
manipulation. The severe phenotype of VDR2/2 mice makes it
difficult to translate accompanying cardiovascular findings to
clinical associations of mild vitamin D deficiency/insufficiency.
However, Weng et al. recently reported an increase in atheroma
burden induced by dietary vitamin D deficiency in LDLR2/2 and
ApoE2/2 models [40]. Again, the contrast with our findings may
be a consequence of the degree of vitamin D manipulation; Weng
et al. commenced vitamin D deficient diets at weaning whereas we
commenced the D-deficient diet at 8 weeks and Schmidt et al.
used a diet that was not completely D-deficient. Nevertheless, both
our intervention and that of Schmidt et al. achieved relative
reductions in 25(OH)D greater than those associated with adverse
cardiovascular outcomes clinically.
Conflicting results have also been reported regarding the effects
of VDR agonists on atherosclerosis burden. Takeda et al. found a
significant reduction in aortic sinus atheroma with the adminis-
tration of oral calcitriol to ApoE2/2 mice [41]. In contrast, Becker
et al. found no benefit of intraperitoneal calcitriol or paricalcitol
administration in ApoE2/2 mice, but an attenuation of unine-
phrectomy-accelerated atherogenesis with paricalcitol [42]. We
used a greater paricalcitol dose than Becker et al., but also found
no suppression of atherogenesis in a non-nephrectomised model. It
is possible that too high a dose of VDR agonist nullifies potential
atherosuppressive benefits of increased VDR signalling. Unlike
our regime, the calcitriol dose administered by Takeda et al. had
no effect on plasma phosphorus and calcium concentrations. We
and others have previously demonstrated that greater dietary
phosphorus exposure accelerates atherogenesis in ApoE2/2 mice
[27,43]. Increased intestinal phosphorus uptake accompanying
excessive VDR agonist use may thus counteract atheroprotective
benefits.
The absence of left ventricular histological or echocardiographic
changes induced by vitamin D deficiency in this study contrasts
with findings from global and cardiomyocyte-specific VDR2/2
mice [20,24]. As with the conflicting atherosclerosis data, this may
reflect differences in the degree of attenuation of VDR signalling.
A strength of our study is the simultaneous characterisation of
the effects of dietary vitamin D deficiency on bone and the
cardiovascular system. Observational clinical data associate
cardiovascular outcomes with lower 25(OH)D levels across a
range that is also associated with significant but small reductions in
bone mineral density [1,5,44]. In our model dietary vitamin D
deficiency induced relative changes in bone mineral density by 12
weeks (i.e. 8 weeks before the cardiovascular assessments) greater
than those associated with variation in vitamin D levels in
community populations [44]. This suggests that the degree of
vitamin D deficiency attained by our intervention approach was
sufficiently severe to be physiologically relevant. Consequently,
cardiovascular pathology induced in more severe models of
vitamin D deficiency may not relate to clinical observations,
though there may of course be species differences in tissue-specific
susceptibility to vitamin D deficiency.
Our model suggests that increased diffuse atherosclerotic
calcification is an earlier sequel of vitamin D-deficiency than
adverse metabolic profile, hypertension and lower nitric oxide
levels. The relevance of this increase to the association of lower
vitamin D levels with cardiovascular outcomes is unclear. Further
work is needed to determine the underlying mechanism(s) and
consequences of this phenomenon. Importantly, cardiovascular
benefits of vitamin D supplementation are currently being
investigated in a large clinical trial [45].
Supporting Information
Figure S1 Effects of 12 weeks vitamin D deficient diet
on plasma 25(OH)D and bone structure. A, plasma
25(OH)D by intervention. B, trabecular bone volume by
intervention. C, trabecular bone mineral density relative to that
of mice fed a vitamin D replete diet. D, representative microCT
images of trabecular bone after 12 weeks of dietary intervention.
n = 4 per group for, data presented as mean (SEM). *p,0.05,
**p,0.01, ****p,0.001. BMD, bone mineral density; TB,
trabecular bone.
(TIF)
Figure S2 Sample images of atheroma characterisation.
A, aortic sinus atheroma stained with Miller’s elastin-van Gieson.
B, thoracic aorta stained for lipid with oil red O. C, Millers’ elastin
van Gieson-stained section with example lipid clefts indicated by
arrows. D, haematoxylin and eosin-stained lesion with some areas
of acellularity marked.
(TIF)
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